Stock Rating Report for PCYC
|
|
Stock Information
| Ticker |
PCYC |
| Company Name |
Pharmacyclics Inc |
| Current Price |
$25.50 |
| Previous Close |
$25.50 |
| Industry |
Drug Manufacturers - Other |
| Sector |
HEALTHCARE |
| Long Stop Loss |
Members Only |
| Short Stop Loss |
Members Only |
| Expected Move |
Members Only |
| Optionable? |
Yes
|
StockProphet Ratings
Join today to see our Technical, Fundamental, and Composite Stock Rating for this stock.
Sector Risks
Chart
We use technical analysis and fundamental analysis to recommend ratings for thousands of stocks. If you had a subscription, this space would show our 3 year history of trades for PCYC. However, we only show it to our subscribers.
We update our ratings and stop losses EVERY WEEK.
Don't miss out on what we recommend for Pharmacyclics Inc next week. Sign up today and start making money!
Demand Fundamentals
|
Demand Technicals
Company Profile
Pharmacyclics, Inc. operates as a clinical-stage biopharmaceutical company focusing on discovering, developing, and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. Its products in clinical development includes PCI-32765, an orally active small molecule inhibitor of Bruton's tyrosine kinase (Btk), which is in phase II studies for the treatment of patients with B-cell lymphoma or leukemia- PCI-27483, an inhibitor of Factor VIIa, which is in phase II clinical trial for the treatment of pancreatic cancer- PCI-24781, a histone deacetylase (HDAC) inhibitor in phase I and II clinical trials in solid tumors and hematological malignancies- HDAC8 Isoform-specific Inhibitor for T-cell leukemia and lymphoma, neuroblastoma, and autoimmune disease. The company's pre-clinical programs include Btk inhibitor program for autoimmune disease- and HDAC8 inhibitor program for cancer. The company has a license agreement with the University of Texas to develop and commercialize porphyrins- expanded porphyrins, such as motexafin gadolinium- and other porphyrin-like substances. It also has a collaboration and license agreement with Servier. The company was founded in 1991 and is headquartered in Sunnyvale, California.
|
Latest News
| Wed, 22 Feb 2012 21:03:02 GMT | Buy Biotech In Phase II For The Best Upside | | Tue, 21 Feb 2012 17:05:38 GMT | Pharmacyclics upgraded by RBC Capital Mkts | | Tue, 21 Feb 2012 11:36:35 GMT | Pharmacyclics upgraded to Outperform from Sector Perform at RBC Capital | | Wed, 15 Feb 2012 18:04:24 GMT | PHARMACYCLICS INC Financials | | Wed, 15 Feb 2012 14:30:00 GMT | Insiders Trading V, PCYC, AAPL | | Tue, 14 Feb 2012 07:25:31 GMT | Watch For The Dips On Pharmacyclics | | Tue, 14 Feb 2012 05:01:23 GMT | Best and worst funds: Mid-cap growth | | Tue, 14 Feb 2012 04:36:20 GMT | Pharmacyclics Is Flying, But There Are Reasons To Be Wary | | Mon, 13 Feb 2012 20:19:36 GMT | Pharmacyclics Shares Popped Again: What You Need to Know | | Mon, 13 Feb 2012 18:19:49 GMT | Nasdaq stocks posting largest percentage increases | | Mon, 13 Feb 2012 18:02:12 GMT | No steep drop seen in Pharmacyclics | | Mon, 13 Feb 2012 14:59:26 GMT | 2 Stocks With Upgrades: Green Mountain Coffee Roasters, Pharmacyclics | | Sat, 11 Feb 2012 14:21:23 GMT | New Star Analyst Rankings for Pharmacyclics, Inc. | | Sat, 11 Feb 2012 13:04:11 GMT | The Week's Top Stock Gainers | | Fri, 10 Feb 2012 23:15:05 GMT | Nasdaq stocks posting largest percentage increases | | Fri, 10 Feb 2012 19:50:36 GMT | Pharmacyclics Shares Surged: What You Need to Know | | Fri, 10 Feb 2012 18:33:09 GMT | Insiders Are Not Buying Into the Rally: Cause for Concern? | | Fri, 10 Feb 2012 18:21:37 GMT | Nasdaq stocks posting largest percentage increases | | Thu, 09 Feb 2012 22:37:09 GMT | Pharmacyclics rises after posting 2Q profit | | Thu, 09 Feb 2012 20:49:43 GMT | PHARMACYCLICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibit | News provided by Yahoo! Finance |
|
|
|
|
